- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BICARA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.09. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 21.08. | Citizens reiterates Bicara Therapeutics stock rating on trial progress | 1 | Investing.com | ||
| 14.08. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 12.08. | Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results | 1 | Benzinga.com | ||
| 11.08. | Bicara Therapeutics stock price target raised to $39 by BTIG | 1 | Investing.com | ||
| 11.08. | Bicara Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 11.08. | Bicara Therapeutics Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.08. | Morgan Stanley raises Bicara Therapeutics stock price target on cash runway | 1 | Investing.com | ||
| 11.08. | Morgan Stanley hebt Kursziel für Bicara Therapeutics an - Liquidität bis 2029 gesichert | 2 | Investing.com Deutsch | ||
| 11.08. | Bicara outlines mid-2027 interim analysis timeline as it initiates FORTIFI-FLEX and names a new CEO and CFO | 1 | Seeking Alpha | ||
| 11.08. | Earnings Call: Bicara Therapeutics meldet Verlust für Q2 2026 - Aktie fällt um 16,66 % | 5 | Investing.com Deutsch | ||
| 11.08. | Bicara Therapeutics announces CEO transition, CFO appointment | 3 | Investing.com | ||
| 11.08. | Bicara Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 11.08. | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | 1.474 | GlobeNewswire (Europe) | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen | |
| 04.08. | Bicara Therapeutics Inc.: Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET | 1 | GlobeNewswire (USA) | ||
| 28.07. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors | 1.588 | GlobeNewswire (Europe) | BOSTON, July 28, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients... ► Artikel lesen | |
| 28.07. | Bicara Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.07. | Bicara Therapeutics Inc.: Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 10.06. | Bicara Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.05. | Cantor Fitzgerald reiterates Bicara Therapeutics stock rating | 4 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | -0,07 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | +2,68 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | -3,45 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | -5,26 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | +2,74 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | +4,10 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | -1,53 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | +5,32 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | BERENBERG stuft QIAGEN NV auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat Qiagen mit einem Kursziel von 40 Euro auf "Hold" belassen. Der Medizintechnik- und Life-Science-Sektor bleibe fundamental attraktiv, wie die... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | -1,16 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | -3,60 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | -4,32 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | -5,21 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | -0,62 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern | ||
| RECURSION PHARMACEUTICALS | 3,830 | +8,19 % | Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript |
BICARA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,050 (+0,22 %) liegt der Kurs bei 22,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BICARA THERAPEUTICS INC finden Sie auf Wallstreet Online.